Executive Summary / Key Takeaways
-
Remarkable Turnaround Execution: Earth Science Tech transformed from a near-bankrupt shell with $1,205 cash in September 2022 to a profitable healthcare holding company generating $26.2 million in revenue and $2.3 million in net income for the nine months ended December 2025. The current valuation suggests the market has not yet fully priced in this transformation.
-
Acquisition-Led Growth with Margin Expansion: The strategy of acquiring and optimizing compounding pharmacies and telemedicine platforms is delivering results. Revenue grew 14% in Q3 2025 while gross margins expanded 700 basis points to 76%, demonstrating that new acquisitions are accretive and management is achieving operational leverage.
-
Capital Allocation Discipline: Management has reduced debt by $929,000, increased equity by $1.95 million, and repurchased 2.19 million shares at an average price of $0.21. With the stock currently trading at $0.0946, these actions signal strong conviction in intrinsic value and a shareholder-first mindset.
-
OTCQB Uplisting as Catalyst: The company is pursuing an OTCQB listing, which would improve liquidity and transparency while potentially attracting institutional interest—a meaningful catalyst for a stock previously constrained by its OTC Pink status.
-
Key Risk Factors: Customer concentration, execution risk in integrating multiple acquisitions, and the challenge of scaling pharmacy licenses across all 50 states represent the primary threats to the investment thesis.
Setting the Scene: From Empty Shell to Healthcare Platform
Earth Science Tech, Inc., originally incorporated in Nevada in 2010 and redomiciled to Florida in June 2022, spent most of its existence as a corporate shell. By September 2022, the company had depleted its resources to just $1,205 in cash while posting a quarterly loss of $228,000. This period forced a shift in strategy toward value creation through acquisition.
The pivot to a strategic holding company in November 2022 marked the inflection point. Management identified fragmented, profitable healthcare services—specifically compounding pharmacies and telemedicine platforms—that could be acquired and optimized through centralized management. This approach de-risks growth by acquiring established cash-generating businesses and capturing synergies through scale.
The company now operates in the personalized medicine sector, where demand for customized medications grows as patients seek alternatives to mass-produced pharmaceuticals. The telemedicine component creates a vertically integrated ecosystem: doctors prescribe, pharmacies compound, and patients receive treatments within a controlled network. This positioning generates recurring revenue, high margins, and increased switching costs for patients and providers.
Business Model and Segment Dynamics: A Work in Progress
Operations span five segments, with the economic engine centered on the compounding pharmacy and telemedicine combination.
Compounding Pharmaceuticals: Legacy Transition
RxCompoundStore.com, the original pharmacy asset, generated $22.4 million in revenue for the nine months ended December 2025, compared to $24.2 million in the prior year. This decline reflects a transition as management focuses growth investments on newer assets. The pharmacy remains profitable and licensed in over 30 states, providing stable cash flow to fund acquisitions.
Mister Meds, acquired in October 2024 and licensed in March 2025, contributed $627,000 in its first partial period. This 5,000 square foot facility includes advanced sterile compounding capabilities with positive and negative pressure environments. Management anticipates that sterile compounding will become a primary revenue driver by addressing a previous gap where injectable medications were outsourced. Bringing this in-house is expected to drive both revenue growth and margin expansion.
Telemedicine: The Growth Accelerator
Peaks Curative, the telemedicine referral platform, saw revenue surge to $1.97 million. This validates the thesis that integrating telemedicine with compounding creates cross-selling synergies. Peaks serves as a patient acquisition engine that feeds directly into the pharmacies, reducing customer acquisition costs and increasing lifetime value.
The March 2026 launch of MyOnlineConsultation.com through MOCTeledoc, LLC, which exited beta as cash-flow-positive, further strengthens this ecosystem. By providing technology and clinical staffing solutions to digital health companies under the Peaks brand, the company is building a vertically integrated telehealth and pharmacy platform capable of national scale. This transforms the business into a technology-enabled healthcare network with higher growth potential.
Non-Core Assets: Pruning for Focus
The consumer brands segment, represented by MagneChef and the BBQraft acquisition, was effectively phased out when the company agreed to sell the BBQraft trademark back for $180,000 in January 2026. This demonstrates a willingness to jettison non-strategic assets and focus capital on the core healthcare platform. The $45,000 loss on this transaction is immaterial relative to the $26 million revenue base, but the move signals improved capital discipline.
Financial Performance: Evidence of Successful Integration
The financial data shows accelerating operational leverage and improving unit economics. For the three months ended December 31, 2025, revenue grew 14% to $8.39 million while net income surged to $910,000. The significant increase in earnings growth relative to revenue growth suggests the company is successfully extracting synergies through procurement savings and overhead consolidation.
Gross margin expansion from 69% to 76% in the same quarter provides further evidence of the benefits of vertical integration. By controlling both the telemedicine platform and the pharmacy, the company captures margin that would otherwise be lost to third parties. Gross margins have remained steady at 73% year-to-date despite the integration of multiple new businesses.
Operating leverage is visible in the expense lines. General and administrative expenses decreased $714,000 for the nine-month period despite adding multiple subsidiaries. Marketing expenses increased $1.57 million as part of an aggressive campaign to drive growth while maintaining profitability.
The balance sheet has also strengthened. Total liabilities decreased $929,000 while stockholders' equity increased $1.95 million, resulting in a debt-to-equity ratio of 0.03. This provides the company with the flexibility to fund acquisitions or accelerate share repurchases without financial stress.
Capital Allocation: Management Conviction
The $5 million share repurchase program, managed by subsidiary Avenvi, LLC, offers insight into management's assessment of value. During the nine months ended December 31, 2025, the company repurchased 2.19 million shares for $466,208—an average price of $0.21 per share. With the stock currently trading at $0.0946, management paid a significant premium to the current market price, signaling a belief that the stock is undervalued.
The company also retired 3.70 million shares for $647,086 during the period. This suggests active management of the capital structure to benefit remaining shareholders. Furthermore, the decision to sell the BBQraft brand at a small loss reinforces the focus on redeploying resources into the core healthcare business.
Outlook and Execution: Ambitious but Achievable
Management projects net income of approximately $4.7 million for fiscal year 2026, representing growth from the $3.3 million delivered in fiscal 2025. This forecast is supported by anticipated cost savings of $1.4 million and the full-year contribution from recent acquisitions.
The planned OTCQB uplisting remains a key strategic objective. Improving financial profiles make this increasingly feasible. An uplisting would likely enhance liquidity, broaden investor access, and improve credibility with acquisition targets and licensing authorities.
The sterile compounding room at Mister Meds represents a significant organic growth driver. Injectable medications command premium pricing and face less competition than oral compounds. Additionally, a hazardous drug room will enable in-house production of testosterone and progesterone creams, which is expected to improve margins by 200-300 basis points once operational.
State licensing expansion continues, with RxCompound currently licensed in over 30 states. While each new license represents a revenue opportunity, the regulatory process remains a variable that could impact growth timing.
Risks: What Could Break the Thesis
Customer concentration is a notable risk, as three customers account for 13% of revenue. Losing a major account could create a revenue headwind. While this concentration reflects success in securing large accounts, it also creates vulnerability to competitive bidding or regulatory changes affecting those clients.
Execution risk on acquisitions is also present. The company has integrated five acquisitions in three years. While early results are positive, the complexity of managing different systems and regulatory requirements increases with each deal.
The regulatory environment for compounding pharmacies is stringent. Any adverse action by the Food and Drug Administration (FDA) or changes to state laws could disrupt operations. Smaller companies often have fewer resources to absorb significant increases in compliance costs.
Liquidity, while improved, requires careful prioritization between acquisitions, licensing expansion, and share repurchases. Unexpected cash needs could impact the pace of growth investments.
Valuation Context: Profitable Growth at a Discount
At $0.0946 per share, the market capitalization is approximately $27.66 million. This represents a valuation of roughly 0.8 times trailing twelve-month revenue and 8.5 times annual net income. These multiples are lower than those typically seen for profitable healthcare services peers.
The price-to-book ratio is 4.73, though the low book value reflects historical factors rather than current asset quality. The enterprise value to EBITDA of 5.46 suggests the stock is valued conservatively based on cash generation.
Management's decision to repurchase shares at $0.21 provides a benchmark for their internal valuation. While the stock trades below that level, the repurchases indicate that insiders saw value at higher prices. The company's strong balance sheet and positive free cash flow further support the valuation case. The current discount appears linked to limited liquidity and the OTC Pink listing rather than financial distress.
Conclusion: A Transformation Waiting to Be Discovered
Earth Science Tech has evolved from a corporate shell into a profitable healthcare platform. The increase in net income relative to revenue growth demonstrates successful integration and margin expansion.
The investment thesis depends on the successful execution of the OTCQB uplisting and the continued expansion of pharmacy licensing and sterile compounding capabilities. If management achieves its fiscal 2026 guidance, the forward earnings multiple would be approximately 5.9 times at current prices.
The primary risks are manageable given the company's balance sheet and execution track record. For investors, the company offers a profile of a growing business trading at a discount to its perceived intrinsic value, with near-term catalysts that could bridge the valuation gap.
